The Three-Layer DNA Stack

Adam O’Dell’s Imperium pitch is, at its core, an argument that DNA is becoming software. The Green Zone Fortunes presentation describes a three-layer stack borrowed from the personal-computer era, and it maps each layer to a specific company. Twist Bioscience (TWST) is the silicon layer, the Intel. Ginkgo Bioworks (DNA) is the software layer, the Microsoft. Absci is the apps layer, the application built on top.

The framing rests on a memorable idea. “Once you can read, design, and write the code of living things,” the pitch runs, “every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.” The “Intel” and “Microsoft” labels trace back to a 2015 comment from Twist’s chief executive, who said “We’re Intel, they’re Microsoft,” when both companies were still startups.

The Two Names at the Center

Twist Bioscience (TWST) is the headline pick, the silicon layer. The company synthesizes DNA on silicon chips using its NanoWell technology, and its financial story is steady: 15 consecutive quarters of revenue growth at roughly 20% a year, a market cap around $7.6 billion, and a position near break-even on an adjusted cash-flow basis. Twist is also an AI story now, with an Eli Lilly drug-discovery deal and an Anthropic collaboration drawing attention through the summer.

Ginkgo Bioworks (DNA) is the software layer, and its story is very different. Founded by five MIT PhDs, Ginkgo was briefly worth around $20 billion in the 2021 SPAC boom and is now worth roughly $539 million. The company has pivoted from selling custom molecules to selling autonomous DNA factories, robotic lab equipment for AI and pharma companies, with a first sale to Novo Nordisk and new government wins with ARPA-H and the NSF.

The Equipment Layer Around Them

Neither of these names exists in a vacuum. The equipment layer around them is crowded with established players. Illumina, Thermo Fisher, and Danaher all compete in the tools and sequencing space that the Imperium thesis builds on. Funders and customers include DARPA, ARPA-H, the NSF, Amazon, Eli Lilly, and Anthropic, all of which have put real money into DNA synthesis and DNA-driven drug discovery.

The presence of those names is actually a point in the theme’s favor. A trend that attracts this much serious capital is not a fringe idea. It also means the two promo picks face deep-pocketed competition, which is part of why sizing the opportunity honestly matters.

The “600 Times Smaller Than Nvidia” Framing

The presentation leans on a specific comparison: the number one Imperium company sits “over 600 times smaller than Nvidia” with a path to becoming the biggest company in the world. The implication is a 600-times runway, and it is the claim to discount the hardest. Being smaller than Nvidia is not, by itself, an opportunity, and a life-sciences tools business is not a chip monopoly.

The same caution applies to the four-month claim that a DNA index returned “more than six times the money” of the semiconductor index. A four-month window is far too short to say anything about a decade-long trend, and the presentation also cites a “55,000%” growth figure for DNA data storage over the next decade, an extrapolation aggressive enough to function as a headline rather than a forecast.

How to Approach the Names

For a deeper look at the two picks, see our TWST stock piece and our Ginkgo Bioworks stock piece. The apps layer is covered in our Absci AI drug discovery teardown.

O’Dell’s track record is worth keeping in view. He teased Palantir in the $20s in spring 2024, and it became the best-performing stock in the S&P 500 for 2024. That is a checkable, dated win, and it is why his framing deserves a fair hearing. But the individual names here carry biotech-level volatility. Twist has a history that includes a prior 95% drawdown, and Ginkgo has already fallen from $20 billion to $539 million. These are watchlist ideas, not certainties. Buy the theme if you believe in it, and size each name like the volatile idea it is.

What the Pitch Gets Right

For all the aggressive numbers, the core of the Imperium pitch is sound. DNA technology really is getting faster and cheaper, and the read, write, and program layers O’Dell describes map to real companies doing real work. Amazon actually set up a DNA program and selected Twist as its silicon layer and Ginkgo as its software layer, which is a modest but verifiable validation of the theme’s direction. The field has drawn real money from DARPA, ARPA-H, the NSF, Amazon, Eli Lilly, and Anthropic, and that breadth of serious buyers is not the profile of a fringe idea.

The difference between the theme and the picks is where most of the risk lives. The theme is broad and durable; the individual names are volatile and specific. A reader can agree with everything O’Dell says about DNA becoming software and still decide that a particular pick is too rich or too early. That is a healthy way to hold the idea: own the trend if you believe in it, and treat each name as a separate bet with its own price discipline.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.